HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer.

AbstractBACKGROUND:
Panitumumab is a full human epidermal growth factor receptor (EGFR) monoclonal antibody, an agent for metastatic colorectal cancer therapy. One of the most general adverse events of anti-EGFR monoclonal antibody therapy is skin disorder. At the present time, although prophylaxis of skin disorder is important for continuation of cancer therapy, there are no effective precautionary treatments.
CASE PRESENTATION:
A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Abound™, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued.
CONCLUSION:
We report that Abound™ was apparently effective in the treatment for anti-EGFR antibody-associated skin disorder. In the future, Abound™ could be expected as an agent for skin disorder as one of the side effects of colorectal cancer therapy.
AuthorsNobuhisa Matsuhashi, Takao Takahashi, Kenichi Nonaka, Kengo Ichikawa, Kazunori Yawata, Toshiyuki Tanahashi, Hisashi Imai, Yoshiyuki Sasaki, Yoshihiro Tanaka, Naoki Okumura, Kazuya Yamaguchi, Shinji Osada, Kazuhiro Yoshida
JournalWorld journal of surgical oncology (World J Surg Oncol) Vol. 12 Pg. 35 (Feb 11 2014) ISSN: 1477-7819 [Electronic] England
PMID24517087 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Dipeptides
  • Valerates
  • arginyl-glutamine
  • beta-hydroxyisovaleric acid
  • Panitumumab
  • EGFR protein, human
  • ErbB Receptors
Topics
  • Aged
  • Antibodies, Monoclonal (adverse effects)
  • Colonic Neoplasms (drug therapy, pathology)
  • Dipeptides (therapeutic use)
  • ErbB Receptors (antagonists & inhibitors, immunology)
  • Humans
  • Lung Neoplasms (drug therapy, secondary)
  • Male
  • Panitumumab
  • Prognosis
  • Skin Diseases (chemically induced, drug therapy)
  • Valerates (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: